The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Disorders

Background:

• Acromegaly is a disorder caused by excess growth hormone (GH) production, often due to pituitary adenomas.
• Octreotide, a somatostatin analog, is used to manage acromegaly by suppressing GH secretion.
• Understanding the optimal mode of octreotide administration is crucial for effective treatment.

Purpose of the Study:

• To compare the effects of continuous subcutaneous octreotide infusion versus bolus injections on 24-hour GH secretion patterns in acromegaly.
• To investigate the impact of different octreotide administration modes on IGF-I levels.
• To explore the regulation of pulsatile GH release by GHRH and somatostatin during octreotide therapy.

Main Methods:

• Six acromegalic patients received octreotide via continuous infusion and bolus injections in a randomized crossover design.
• 24-hour GH secretion profiles were monitored, along with responses to GHRH stimulation tests.
• Serum GH and IGF-I levels were analyzed using validated assays and GH pulse detection algorithms.

Main Results:

• Both continuous and bolus octreotide significantly reduced mean 24-hour GH levels and IGF-I concentrations.
• Continuous infusion demonstrated a more pronounced suppression of mean GH levels compared to bolus injections (P < 0.05).
• Octreotide treatment inhibited GH pulse amplitude but did not alter pulse frequency, irrespective of administration mode.

Conclusions:

• Continuous subcutaneous octreotide is more effective than bolus injections in suppressing mean GH levels in acromegaly.
• The unchanged GH pulse frequency suggests a pituitary-derived mechanism, independent of hypothalamic GHRH and somatostatin.
• Octreotide therapy effectively manages GH and IGF-I levels in acromegaly, with continuous infusion offering enhanced GH suppression.